http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005002586-A8

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82559a0ed7e94b382acc3e233e9a7430
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_972d2e148521e9ed5f668e0de7244112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_34cc545b739b113e6b3979f5ad84f1b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_abd8c0613fe1970166f7649292ea69ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a8566fb78653f30af25ffa64cf2b7a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8adf1aa119f2fa8c92dc31e5ef07b387
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-554
filingDate 2004-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_826cbc66d8912738abc6f9de2844da85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecf30a34b5c8c07c8794ce2d705f70f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2052149c97ff73dd7f1edf6b9c4ecce1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0518fce4e3cffb87c04aa5e1694527af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f9257dd969eccc154dc5de6ecf4d623
publicationDate 2006-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2005002586-A8
titleOfInvention Metabolite of quetiapine
abstract A method of treating anxiety, agitation, hostility, panic, eating disorders, affective symptoms, mood symptoms, negative and positive psychotic symptoms commonly associated with schizophrenia, dementia, anxiety, depression, mood disorders, bipolar disorders, bipolar mania, bipolar depression, cognitive disorders and neurodegenerative disorders comprising administering an effective amount of Formula (I) or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula (I) or its pharmaceutically acceptable salt and at least on pharmaceutically acceptable carrier or diluent.
priorityDate 2003-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399230
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492896
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5002

Total number of triples: 32.